Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
7VjY7pEywrc6scCs
